Arketamine for bipolar depression: Open-label, dose-escalation, pilot study

2023/06/24 by Gustavo C. Leal, Fernanda S. Correia‐Melo, Fernanda S. Correia-Melo +17 · 1 voice
Medicine · Neuroscience · #Bipolar Disorder and Treatment #Treatment of Major Depression #Tryptophan and brain disorders

paper · doi:10.1016/j.jpsychires.2023.06.028

openalex publication_date 2023/06/24 · crossref created 2023/06/24 · crossref issued 2023/08/01 · crossref published 2023/08/01 · crossref published-print 2023/08/01 · crossref deposited 2025/09/20 · openalex created_date 2025/10/10 · crossref indexed 2026/06/03 · openalex updated_date 2026/07/29

Citations

• A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Discussions

• Proud to share my latest first authorship! This is the first clinical trial testing IV arketamine for bipolar depression. Subjects received two infusions one week apart—0.5 mg/kg first and then 1 mg/k [bsky, 5 points, 1 comments]